Evidence map›Paper›PMID 28945764›Full record

ArticlePloS one2017

High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype.

Daisuke Koyama, Makoto Murata, Ryo Hanajiri, Shingo Okuno, Sonoko Kamoshita, Jakrawadee Julamanee, Erina Takagi, Daiki Hirano, Kotaro Miyao, Reona Sakemura and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Daisuke KoyamaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Makoto MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0001-5488-4364
Ryo HanajiriDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Shingo OkunoDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Sonoko KamoshitaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Jakrawadee JulamaneeDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Erina TakagiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Daiki HiranoDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Kotaro MiyaoDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Reona SakemuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Tatsunori GotoDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Fumihiko HayakawaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Aika SetoDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan.
Koichi MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan.
Seitaro TerakuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Tetsuya NishidaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Nagoya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regenerating islet-derived protein 3 alpha (REG3A) is a biomarker of lower gastrointestinal graft-versus-host disease (GVHD); however, the biological role of REG3A in the pathophysiology of GVHD is not understood. Here, we examined the association between a single nucleotide polymorphism in the REG3A gene, rs7588571, which is located upstream and within 2 kb of the REG3A gene, and transplant outcomes including the incidence of GVHD. The study population consisted of 126 adult Japanese patients who had undergone bone marrow transplantation from a HLA-matched sibling. There was no association between rs7588571 polymorphism and the incidence of acute GVHD. However, a significantly higher incidence of extensive chronic GVHD was observed in patients with the rs7588571 non-GG genotype than in those with the GG genotype (Odds ratio 2.6; 95% confidence interval, 1.1-6.0; P = 0.029). Semi-quantitative reverse transcription PCR demonstrated that the rs7588571 non-GG genotype exhibited a significantly lower REG3A mRNA expression level than the GG genotype (P = 0.032), and Western blot analysis demonstrated that the rs7588571 non-GG genotype exhibited a trend toward lower REG3A protein expression level than the GG genotype (P = 0.053). Since REG proteins have several activities that function to control intestinal microbiota, and since intestinal dysbiosis is in part responsible for the development of GVHD, our findings lead to the novel concept that REG3A could have some protective effect in the pathogenesis of GVHD through the regulation of gut microbiota.

Indexed as

AdolescentAdultAntigens, NeoplasmAsian PeopleBiomarkers, TumorBone Marrow TransplantationChronic DiseaseFemaleGastrointestinal MicrobiomeGene ExpressionGenotypeGraft vs Host DiseaseHumansIncidenceJapanLectins, C-TypeAntigens, NeoplasmBiomarkers, TumorLectins, C-TypePancreatitis-Associated ProteinsREG3A protein, humanRNA, Messenger

Identifiers

PMID28945764
PMCPMC5612655
OpenAlexW2760659673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.